retatrutide nonalcoholic steatohepatitis nash trial fatty liver disease Fatty Liver Disease and Fibrosis (NASH) Clinical Trial retatrutide nonalcoholic steatohepatitis nash trial

its job is tolerability, not efficacy

Because the gut is intimately connected to the immune and central nervous systems, reducing the antigenic load of undigested proteins can have profound downstream effects on systemic symptoms

Always consult with your healthcare provider before starting any new medication, particularly if you have pre-existing health conditions

If you have concerns about your symptoms or treatment, consult your healthcare provider.

This dysfunction may be caused by the inhibition of multiple enzymes and/or transporter proteins involved in fatty acid -oxidation metabolism by VPA ( Studies on the inhibitory effect of VPA on mitochondrial fatty acid -oxidation have shown that VPA has different inhibitory effects on fatty acid oxidation of different chain lengths

Always disclose your complete medical history and medications to your provider before starting